On Rare Disease Day, Adalvo highlights its commitment to expanding access to essential treatments for patients with rare diseases.
With a targeted portfolio, Adalvo continues to address unmet medical needs by providing high-quality differentiated solutions. Highlights include:
Additionally, DCP submissions for Bosutinib, Ibrutinib, and Nintedanib are underway, while Ambrisentan + Tadalafil is set for submission in the coming weeks, following four successful pivotal BE studies. Recent approvals for Macitentan and Riociguat continue to strengthen Adalvo’s cardiovascular offering, ensuring broader access to life-changing treatments.
In oncology, Lenalidomide has been launched across multiple European countries, holding exclusivity as the first and only supplier in Brazil for three years.
Expansion continues with Pazopanib now available across Africa, Latin America, and Europe, alongside the wider rollout of Pomalidomide in key European markets.
Join us in shaping the future of healthcare. For collaboration opportunities, contact our Global Business Development team.
Partner with Us Today